Biomap (Beijing) Intelligent Technology Co Ltd. has entered into a strategic collaboration with Sanofi SA to co-develop cutting-edge artificial intelligence (AI) modules for biotherapeutic drug discovery by leveraging Biomap’s AI platform.

Circio Holding ASA and Neoregen Biotech have commenced a research collaboration on novel circular RNA (circRNA) therapeutics based on Circio’s proprietary Circvec technology. The technology is composed of a modular genetic cassette design for efficient biogenesis of multifunctional circRNAs that can be adapted and applied to multiple purposes.

Scientists at the Guangzhou Institutes of Biomedicine and Health have developed a humanized kidney at the mesonephros stage in pig embryos up to day 28 of gestation. It is the first time that this has been achieved in chimeric xenotransplants.

Integral Molecular Inc. has been awarded funding totaling $896,000 from the National Institutes of Health (NIH), which will support its discovery of antibodies against difficult and conserved protein targets.

Twist Bioscience Corp. has entered into an antibody discovery, option and license agreement with Bayer AG.

Quantum dots, a phenomenon in quantum physics that alters the energy of electrons and changes the properties of particles, caught the attention of the Royal Swedish Academy of Sciences (KVA) for the 2023 Nobel Prize in Chemistry. Alexei Ekimov and Louis Brus received the award for their discovery; Moungi Bawendi, for developing its applications. With their work, “in equal shares,” said the Secretary General of KVA Hans Ellegren, the three scientists have laid the foundations of nanotechnology, a tool that we see today in our homes, on televisions and LED lamps, or in laboratories and hospitals for designing new drugs or new strategies against cancer.

Complementarity-determining regions (CDRs) are relatively short peptide loops in antibodies where they bind to their specific antigens. Bovines, unlike humans and other vertebrates, rely on ultralong CDR H3 antibody knob regions to neutralize cryptic viral epitopes.

Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine.

Quris Technologies Ltd. (Quris-AI) and Merck KGaA have extended their collaboration after a successful initial preclinical study of Quris-AI’s BioAI drug safety platform.